Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

2012226 citationsJournal Articlebronze Open Access

Authors

Éric Bouffet · BC Children's Hospital

Regina I. Jakacki · BC Children's Hospital

Stewart Goldman · BC Children's Hospital

Darren Hargrave · BC Children's Hospital

Cynthia Hawkins · BC Children's Hospital

Manohar Shroff · BC Children's Hospital

Juliette Hukin ·

Abstract

Weekly vinblastine seems to be a reasonable alternative to radiation for pediatric patients with LGG who have experienced treatment failure with first-line chemotherapy. The 5-year progression-free survival observed in this phase II trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. The role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deserves further investigation.

Topics & Keywords

Glioma Diagnosis and Treatment Neuroblastoma Research and Treatments Meningioma and schwannoma management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 12, pp. 1358-1363

DOI: 10.1200/jco.2011.34.5843

Field-Weighted Citation Impact: 7.58